Oct 10 China patent allowed for NODJul 22 - Dynavax Appoints Daniel Kisner, M.D. to Board of DirectorsJul 13 - MerLion Pharmaceuticals Completes US$7 Million Series C Financing RoundJul 8 - Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIRJul 7 - Dynavax Initiates First Human Trial in Universal Flu Vaccine ProgramJun 16 - NATURE Publishes New Dynavax Findings on Novel Role of TLRs in LupusMay 6 - Dynavax Completes Over 2000 First Immunizations in Phase 3 StudyApr 28 - Kiadis Pharma Provides ATIR Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related MortalityApr 26 - Dynavax Reports Positive Data on Universal Flu Vaccine CandidateMar 29 - Juvista EU Phase III Trial Fully Recruited and On Schedule to Report Data in H1 2011
Mar 2 - Renovo and Shire revised licensing deal for JuvistaFeb 18 - Dynavax and GlaxoSmithKline Select Clinical Candidate in the Endosomal TLR Inhibitor ProgramFeb 8 - Dynavax Initiates Large-Scale Phase 3 Trial of HEPLISAV